Max-Delbrück-Centrum für Molekulare Medizin has a total of 14 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2015. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are ARIAD GENE THERAPEUTICS INC, HIPPOCAMPE and SIBTECH INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | United States | 4 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry | |
#4 | Foods and drinks | |
#5 | Agriculture |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Heterocyclic compounds | |
#6 | Enzymes | |
#7 | Acyclic or carbocyclic compounds | |
#8 | Measuring microorganism processes | |
#9 | Special acyclic compounds | |
#10 | Animal care |
# | Name | Total Patents |
---|---|---|
#1 | Schütz Anja | 4 |
#2 | Specker Edgar | 4 |
#3 | Uckert Wolfgang | 4 |
#4 | Bader Michael | 4 |
#5 | Grohmann Maik | 4 |
#6 | Nazaré Marc | 4 |
#7 | Mallow Keven | 4 |
#8 | Matthes Susann | 4 |
#9 | Blankenstein Thomas | 3 |
#10 | Marino Stephen | 2 |
Publication | Filing date | Title |
---|---|---|
WO2017211900A1 | Chimeric antigen receptor and car-t cells that bind bcma | |
EP3275885A1 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | |
WO2016156469A1 | Genome architecture mapping on chromatin | |
EP3219800A1 | A transposon-based transfection system for primary cells | |
EP3219803A1 | Enhanced sleeping beauty transposons, kits and methods of transposition | |
EP3156067A1 | High avidity hpv t-cell receptors |